![](https://webarchive.library.unt.edu/web/20081010122851im_/http://www.nci.nih.gov/images/spacer.gif) |
¿Preguntas sobre el cáncer?
![](https://webarchive.library.unt.edu/web/20081010122851im_/http://www.nci.nih.gov/images/spacer.gif)
|
1-800-422-6237
(1-800-4-CANCER)
|
![](https://webarchive.library.unt.edu/web/20081010122851im_/http://www.nci.nih.gov/images/spacer.gif)
|
Llame de lunes a viernes de 9:00 a.m. a 4:30 p.m., hora local en Estados Unidos y sus territorios. |
|
![](https://webarchive.library.unt.edu/web/20081010122851im_/http://www.nci.nih.gov/images/spacer.gif) |
|
![](https://webarchive.library.unt.edu/web/20081010122851im_/http://www.nci.nih.gov/images/spacer.gif)
![](https://webarchive.library.unt.edu/web/20081010122851im_/http://www.nci.nih.gov/images/spacer.gif)
| Sustancia en estudio para el tratamiento de cáncer. Se elabora enlazando el anticuerpo monoclonal 170, que se une a la proteína MUC-1, con una sustancia llamada 2IT-BAD, que se une con sustancias radiactivas. El anticuerpo monoclonal 170 2IT-BAD se puede usar para detectar células cancerosas y destruirlas. Es un tipo de inmunoconjugado. |
![](https://webarchive.library.unt.edu/web/20081010122851im_/http://www.nci.nih.gov/images/spacer.gif)
![](https://webarchive.library.unt.edu/web/20081010122851im_/http://www.nci.nih.gov/images/gray_spacer.gif)
![](https://webarchive.library.unt.edu/web/20081010122851im_/http://www.nci.nih.gov/images/spacer.gif)
|
![](https://webarchive.library.unt.edu/web/20081010122851im_/http://www.nci.nih.gov/images/spacer.gif) |